AVL-292 (benzenesulfonate) is primarily investigated for its potential in targeting Bruton's tyrosine kinase (BTK), a key enzyme in B-cell receptor signaling. Its application is focused on the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, where inhibiting BTK can disrupt the survival and proliferation of cancerous B-cells. Additionally, it is being explored for autoimmune diseases, as BTK inhibition can modulate immune responses by affecting B-cell activity. Research is ongoing to evaluate its efficacy, safety, and potential as a therapeutic agent in clinical settings.